Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fairness and transparency in medical journals.
Elston DM, Grant-Kels JM, Levin N, Alam M, Altman EM, Brodell RT, Fernandez AP, Hurley MY, Maize J, Ratner D, Schaffer J, Kantor J. Elston DM, et al. Among authors: hurley my. J Am Acad Dermatol. 2021 Jul;85(1):31-32. doi: 10.1016/j.jaad.2020.10.027. Epub 2020 Nov 4. J Am Acad Dermatol. 2021. PMID: 33157176 No abstract available.
Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology.
Vidal CI, Armbrect EA, Andea AA, Bohlke AK, Comfere NI, Hughes SR, Kim J, Kozel JA, Lee JB, Linos K, Litzner BR, Missall TA, Novoa RA, Sundram U, Swick BL, Hurley MY, Alam M, Argenyi Z, Duncan LM, Elston DM, Emanuel PO, Ferringer T, Fung MA, Hosler GA, Lazar AJ, Lowe L, Plaza JA, Prieto VG, Robinson JK, Schaffer A, Subtil A, Wang WL. Vidal CI, et al. Among authors: hurley my. J Cutan Pathol. 2018 Aug;45(8):563-580. doi: 10.1111/cup.13142. Epub 2018 Jun 7. J Cutan Pathol. 2018. PMID: 29566273 Free article.
Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology.
Task Force/Committee Members; Vidal CI, Armbrect EA, Andea AA, Bohlke AK, Comfere NI, Hughes SR, Kim J, Kozel JA, Lee JB, Linos K, Litzner BR, Missall TA, Novoa RA, Sundram U, Swick BL, Hurley MY; Rating Panel; Alam M, Argenyi Z, Duncan LM, Elston DM, Emanuel PO, Ferringer T, Fung MA, Hosler GA, Lazar AJ, Lowe L, Plaza JA, Prieto VG, Robinson JK, Schaffer A, Subtil A, Wang WL. Task Force/Committee Members, et al. Among authors: hurley my. J Am Acad Dermatol. 2019 Jan;80(1):189-207.e11. doi: 10.1016/j.jaad.2018.04.033. Epub 2018 Apr 22. J Am Acad Dermatol. 2019. PMID: 29689323
Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores.
Task Force/Committee Members; Vidal CI, Sutton A, Armbrect EA, Lee JB, Litzner BR, Hurley MY; Rating Panel; Alam M, Duncan LM, Elston DM, Emanuel PO, Ferringer T, Fung MA, Hosler GA, Lazar AJ, Lowe L, Plaza JA, Robinson JK, Schaffer A. Task Force/Committee Members, et al. Among authors: hurley my. J Cutan Pathol. 2019 Jul;46(7):484-489. doi: 10.1111/cup.13459. Epub 2019 Apr 26. J Cutan Pathol. 2019. PMID: 30895633 Free article.
Dermatopathologic features of cutaneous squamous cell carcinoma and actinic keratosis: Consensus criteria and proposed reporting guidelines.
Christensen RE, Elston DM, Worley B, Dirr MA, Anvery N, Kang BY, Bahrami S, Brodell RT, Cerroni L, Elston C, Ferringer T, Hurley MY, Garton K, Lee JSS, Liu Y, Maize JC, McNiff JM, Rapini RP, Sangueza OP, Shea CR, Zhou C, Alam M. Christensen RE, et al. Among authors: hurley my. J Am Acad Dermatol. 2023 Jun;88(6):1317-1325. doi: 10.1016/j.jaad.2022.12.057. Epub 2023 Feb 24. J Am Acad Dermatol. 2023. PMID: 36841336 Review.
Letter from the journal: Improving diagnostic acumen and patient outcomes.
Elston DM, Grant-Kels JM, Levin NA, Alam M, Brodell RT, Fernandez AP, Flamm A, Hurley MY, Ratner D, Schaffer JV, Peebles K, Alexis AF, James AJ. Elston DM, et al. Among authors: hurley my. J Am Acad Dermatol. 2023 Sep;89(3):471-472. doi: 10.1016/j.jaad.2023.05.009. Epub 2023 May 10. J Am Acad Dermatol. 2023. PMID: 37172734 No abstract available.
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW, Chu MB, Armbrecht E, Galperin T, Potts GA, Mattox A, Kurta A, Polito K, Slutsky JB, Burkemper NM, Hurley MY. Fosko SW, et al. Among authors: hurley my. J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10. J Am Acad Dermatol. 2020. PMID: 31836564 Clinical Trial.
80 results